New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Ventricular remodeling is a key pathological process in heart failure (HF), impacting cardiac structure and function.
• Continuous stimuli like pressure overload and ischemia drive ventricular remodeling, worsening HF prognosis.
• Sodium glucose cotransporter 2 inhibitors (SGLT2i) are emerging cardiovascular protective agents beyond their hypoglycemic effects.

Purpose of the Study:

• To investigate the molecular mechanisms by which SGLT2 inhibitors ameliorate ventricular remodeling.
• To explore the cardiovascular protective effects of SGLT2 inhibitors in the context of ventricular remodeling.
• To establish strategies for preventing heart failure progression by targeting ventricular remodeling with SGLT2 inhibitors.

Main Methods:

• Review of recent clinical trials and animal experiments on SGLT2 inhibitors.
• Analysis of molecular pathways involved in SGLT2 inhibition and ventricular remodeling.
• Synthesis of evidence linking SGLT2 inhibitor mechanisms to cardiovascular protection.

Main Results:

• SGLT2 inhibitors demonstrate significant cardiovascular protective roles in various conditions associated with ventricular remodeling, including heart failure, myocardial infarction, and diabetic cardiomyopathy.
• Evidence suggests that the cardioprotective effects of SGLT2 inhibitors are intrinsically linked to their ability to inhibit ventricular remodeling.
• Inhibition of ventricular remodeling by SGLT2 inhibitors can lead to improved readmission rates and reduced mortality in heart failure patients.

Conclusions:

• SGLT2 inhibitors offer a promising therapeutic strategy for mitigating ventricular remodeling and improving cardiovascular outcomes.
• Understanding the molecular mechanisms underlying SGLT2 inhibitor action is crucial for optimizing their use in cardiovascular disease management.
• Targeting ventricular remodeling with SGLT2 inhibitors represents a viable approach to prevent and manage heart failure progression.